микробиота. Обзоры литературы
 Скачать 216.54 Kb.
|
|
ЛИТЕРАТУРА (LITERATURE) 1. Collins C.D., Purohit S., Podolsky R.H. et al. The application of genomic and proteomic technologies in predictive, pre- ventive and personalized medicine. Vascul Pharmacol 2006; 45: 5: 258–267. 2. Бондаренко В.М., Рыбальченко О.В. Анализ профилактического и лечебного действия пробиотических препаратов с позиций новых научных технологий. Журн микро- биол 2015; 2: 90–104. (Bondarenko V.M., Rybalchenko O.V. Analysis of prophylactic and therapeutic action of probiotic preparations from the standpoint of new scientific technolo- gies. Zh Mikrobiol 2015; 2: 90–104.) 3. Lederberg J. Infectious history. Science 2000; 444: 287–293. 4. Бондаренко В.М. Обоснование и тактика назначения в медицинской практике различных форм пробиотиче- ских препаратов. Фарматека 2012; 13: 77–87. (Bondaren- ko V.M. The rationale and tactics of destination in medical practice of different forms of probiotic preparations. Farmate- ka 2012; 13: 77–87). 5. Turnbaugh P.J., Hamady M., Yatsunenko T. et al. A core gut mi- crobiome in obese and lean twins. Nature 2009; 457: 480– 484. 6. Nielsen D.S., о P.L., Rosenfeldt V. et al. Case study of the distribution of mucosa-associated Bifidobacterium species, Lactobacillus species, and other lactic acid bacte- ria in the human colon. Appl Environ Microbiol 2003; 69: 12: 7545–7548. 7. Парфенов АИ, Бондаренко В.М. Что нам дал вековой опыт познания симбионтной кишечной микрофлоры. Тер архив 2012; 2: 5-10. (Parfenov A.I., Bondarenko V.M. That gave us a century of experience of knowledge of symbi- otic intestinal microflora. Ter arkhiv 2012; 2: 5–10). 8. Рыбальченко О.В. Электронно-микроскопическое исследование межклеточных взаимодействий микро- 25 Мазанкова Л.Н. и соавт. Пробиотики в педиатрии за и против с позиции доказательной медицины РОССИЙСКИЙ ВЕСТНИК ПЕРИНАТОЛОГИИ И ПЕДИАТРИИ, 1, 2016 ROSSIYSKIY VESTNIK PERINATOLOGII I PEDIATRII,1, организмов при антагонистическом характере взаимоотношений. Микробиология 2006; 75: 4: 550–555. (Rybalchenko O.V. Electron microscopic study of intercel- lular interactions of microorganisms with antagonistic nature of the relationship. Mikrobiologiya 2006; 75: 4: 550–555.) 9. Лиходед В.Г., Бондаренко В.М., Гинцбург А.Л. Экзогенные и эндогенные факторы в патогенезе атеросклероза. Рецепторная теория атерогенеза. Рос кардиол журн 2010; 2: 92–96. (Likhoded V.G., Bondarenko V.M., Gintsburg A.L. Exogenous and endogenous factors in the pathogenesis of ath- erosclerosis. Receptor theory of atherogenesis. Ros kardiol zhurn 2010; 2: 92–96.) 10. Дисбиоз кишечника. Руководство по диагностике иле- чению. Под ред. Е.И. Ткаченко, АН. Суворова. СПб.: СпецЛит 2007; 238. (Intestinal dysbiosis. Guidance on diag- nostics and treatment. E.I. Tkachenko, A.N. Suvorov (eds). SPb.: Spetslit, 2007; 238.) 11. Шендеров Б.А. Роль персонального функционального питания в современных программах медицины антистаре- ния. Вестн восстанов мед 2009; 3: 9–17. (Shenderov B.A. functional Role of personal power in the contemporary medi- cine the anti-aging. Vestn vosstanov med 2009; 3: 9–17.) 12. Рыбальченко О.В., Бондаренко В.М., Добрица В.П. Атлас ультраструктуры микробиоты кишечника человека. Изд-во СПб. ИИЦ ВМА 2008; 102. (Rybalchenko O.V., Bondarenko V.M., Dobrica V.P. Atlas of the ultrastructure of the microbiota of the human intestine. Publishing house of SPb. IRC. VMA, 2008; 102.) 13. Чернин В.В., Бондаренко В.М., Червинец В.М., Базлов С.Н. Дисбактериоз мукозной микрофлоры эзофагогастродуоде- нальной зоны. М МИА 2011; 144. (Chernin V.V., Bondaren- ko V.M., Chervinec V.M., Bazlov S.N. Dysbacteriosis of mucosal microflora esophago-gastroduodenal zone. M: MIA 2011; 144.) 14. Бондаренко В.М., Лиходед В.Г. Распознавание коммен- сальной микрофлоры образраспознающими рецепторами в физиологии и патологии человека. Журн микробиол 2012; 3: 82 89. (Bondarenko V.M., Likhoded V.G. Recogni- tion of commensal microflora by pattern recognition receptors in human physiology and pathology. Zhurn mikrobiol 2012; 3: 82–89.) 15. Ардатская М.Д., Минушкин ОН Современные принципы диагностики и фармакологической коррекции. Consilium Medicum Гастроэнтерология 2006; 8: 2. (Ardats- kaya M.D., Minushkin O.N. Modern principles of diagnosis and pharmacological correction. Consilium Medicum Gas- troehnterologiya 2006; 8: 2.) 16. Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром современное состояние проблемы. Руководство для врачей М ГЭОТАР–Медиа 2007; 304. (Bondarenko V.M., Matsu- levitch T.V. Dysbacteriosis of the intestine as clinical and laboratory syndrome: the state of the art. The guide for physi- cians. M.: GEOTAR–Media, 2007: 304.) 17. FAO/WHO. Working group on drafting guidelines for the evaluation of probiotics in food. Guidelines for the evaluation of probiotics in food. 2002; http://ftp. fao. org/es/esn/food/ wgreport2.pdf 18. Probiotic bacteria in dietetic products for infants: a commen- tary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr 2004; 38: 365–374. 19. Borchers A.T. Probiotics and immunity. J Gastroenterol 2009; 4: 26–46. 20. Ng S.C., Hart A.L., Kamm M.A. et al. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 2: 301–312. 21. Resta-Lenert S., Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection. Gut 2003: 52: 7: 988–997. 22. Ouwehand A., Isolauri E., Salminen S. The role of intestinal microflora for development of the immune system in early childhood. Eur J Nutr 2002; 41: 1: 132–137. 23. Duary R.K., Rajput Y.S., Batish V.K., Grover S. Assessing the adhesion of putative indigenous probiotic lactobacilli to human colonic epithelial cells. Indian J Med Res 2011; 134: 5: 664–671. 24. Yan F., Polk D.B. Probiotic bacterium prevents cytokine- induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277: 50959–50965. 25. Braat H., Van Den B.J., Van Tol E. et al. Lactobacillus rham- nosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am J Clin Nutr 2004; 80: 1618–1625. 26. Fang H., Elina T., Heikki A. et al. Modulation of humoral im- mune response through probiotic intake. Immunol Med Mi- crobiol 2000: 29: 47–52. 27. Szajewska H., Setty M., Mrukowicz J., Guandalini S. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 2006; 42: 454–475. 28. Szajewska H., Karas J. Acute gastroenteritis. The COMMENT working group on acute diarrhea: Where are we now and where are we going? J Clin Gastroenterol 2014; 48: Suppl 1: S32–33. 29. Shamir R., Makhoul I.R., Etzioni A. et al. Evaluation of a diet containing probiotics and zinc for the treatment of mild diar- rheal illness in children younger than one year of age. J Am Coll Nutr 2005; 24: 370–375. 30. Isolauri E., Juntunen M., Rautanen T. et al. A human Lacto- bacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991; 88: 90–97. 31. Shornikova A.V., Isolauri E., Burkanova L. et al. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhea. Acta Paediatr 1997; 86: 460–465. 32. Guarino A., Canani R.B., Spagnuolo M.I. et al. Oral bacterial therapy reduces the duration of symptoms and of viral excre- tion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997; 25: 516–519. 33. Guandalini S., Pensabene L., Zikri M.A. et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastro- enterol Nutr 2000; 30: 54–60. 34. Guarino A., Ashkenazi S., Gendrel D. et al. ESPGHAN/Euro- pean Pediatric Infectious Disease evidence-based guidelines for the management of acute gastroenteritis in children in Eu- rope, update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 1: 132–152. 35. Johnston B.C., Goldenberg J.Z., Vandvik P.O. et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827. 36. Applegate J.A., Christa L.F.W., Ramya A., Robert E.B. System- atic review of probiotics for the treatment of community- ac- quired acute diarrhea in children. BMC Public Health 2013; 13: Suppl 3: S16. 37. Применение пробиотиков при острых гастроэнтеритах. Consilium medicum Педиатрия 2014; 4: 53-58. (The use of probiotics in acute gastroenteritis. Consilium medicum Pe- diatriya 2014; 4: 53–58.) 38. Мазанкова Л. Н, Яковлева Г.Ю., Ардатская М.Д. Ротави- русная инфекция у детей раннего возраста обоснование пробиотической терапии. Дет инф 2011; 2: 52–56. (Ma- zankova L.N., Yakovleva G.Y., Ardatskaya M.D. Rotavirus in- fection in infants: rationale of probiotic therapy. Det inf 2011; 2: 52–56.) 39. WGO. Probiotics and Prebiotics. World Gastroenterol- ogy Organization, 2011; http://www. worldgastroenterology. org/assets/export/userfiles/2012%20 Probiotics_ NEW%20 FINAL_sp. pdf. 40. Szajewska H., Ruszczyński M, Radzikowski A. Probiotics in the prevention of antibioticassociated diarrhea in children: a me- ОБЗОРЫ ЛИТЕРАТУРЫ РОССИЙСКИЙ ВЕСТНИК ПЕРИНАТОЛОГИИ И ПЕДИАТРИИ, 1, 2016 ROSSIYSKIY VESTNIK PERINATOLOGII I PEDIATRII,1, 2016 ta-analysis of randomized controlled trials. J Pediatr 2006; 149: 367–372. 41. Johnston B.C., Supina A.L., Ospina M. et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Co- chrane Database Syst Rev 2007; 2: CD004827. 42. Lynne V. McFarland. Probiotics for the Primary and Second- ary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics 2015; 4: 160–178. 43. Saavedra J. Probiotics and infectious diarrhea. Am J Gastro- enterol 2000; 95: Suppl 1: 16–18. 44. Surawicz C.M. Probiotics, antibiotic-associated diarrhea and Clostridium difficile diarrhea in humans. Best Pract Res Clin Gastroenterol 2003; 17: 775–783. 45. Malfertheiner P., Megraud F., O’Morain C.A. et al. Manage- ment of Helicobacter pylori infection – the Maastricht IV/ Florence Consensus report. Gut 2012; 61: 646–664. 46. Moayyedi P., Ford A.C., Talley N.J. et al. The efficacy of pro- biotics in the therapy of irritable bowel syndrome: a systemic review. Gut 2008; 64: 654–667. 47. Bin-Nun A., Bromiker R., Wilschanski M. et al. Oral probiot- ics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147: 192–196. 48. Lin H.C., Su B.H., Chen A.C. et al. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2005; 115: 1–4. 49. Wolvers D., Antoine J., Myllyluoma E. et al. Guidance for substantiating the evidence for beneficial effects of probiot- ics: prevention and management of infections by probiotics. J Nutr 2010; 140: 698–712. 50. Alfaleh K., Anabrees J., Bassler D. et al. Probiotics reduce the risk of necrotizing enterocolitis in preterm infants: a meta- analysis. Neonatology 2010; 97: 93–99. 51. Hunter C., Mary A., Peter G. et al. Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight 1000 grams: a se- quential analysis. BMC Pediatr 2012; 12: 142. 52. Mercenier A., Pavan S., Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003; 9: 2: 175–191. 53. Borriello S.P., Hammes W.P., Holzapfel W. et al. Safety of pro- biotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 2003; 36: 775–780. 54. Karpa K.D. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother 2007; 41: 1284–1287. 55. Snydman D.R. The safety of probiotics. Clin Infect Dis 2008; 46: Suppl 2: 104–111. 56. Probiotics Pros and Cons. BERKELEY WELLNESS, 2014; http: www. berkeleywellness. com›…article/probiotics…and- cons. 57. Kunz A.N., Noel J.M., Fairchok M.P. Two cases of Lactoba- cillus bacteremia during probiotic treatment of short gut syn- drome. Pediatr Gastroenterol Nutr 2004; 38: 4: 457– 458. 58. Soleman N., Laferl H., Kneifel W. et al. How safe is safe? A case of Lactobacillus paracasei ssp. paracasei endocarditis and dis- cussion of the safety of lactic acid bacteria. Scand J Infect Dis 2003; 35: 10: 759–762. 59. Salminen M.K., Tynkkynen S., Rautelin H. et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lacto- bacillus rhamnosus GG in Finland. Clin Infect Dis 2002; 35: 10: 1155–1160. 60. Liong M.T. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66: 4: 192–202. 61. Besselink M.G., van Santvoort H.C., Buskens E. et al. Probi- otic prophylaxis in predicted severe acute pancreatitis: a ran- domised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651–659. 62. Gou S., Yang Z., Liu T., Wu H., Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2014; 18: 2: R57. 63. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83: 1256–1264. 64. Marteau P., Shanahan F. Basic aspects and pharmacology of probiotics an overview on pharmacokinetics, mechanisms of action and side effects. Best Pract Res Clin Gastroenterol 2003; 17: 5: Поступила 09.11.15 |